DOCSLIB.ORG

8694 Medical Single 006

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
8694 Medical Single 006 Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Oxford University Hospitals NHS Foundation Trust Issue No: 006 Issue date: 13 August 2020 Oxford Medical Genetics Contact: Carolyn Campbell Laboratories Tel: +44 (0) 1865-226001 Churchill Hospital E-Mail: [email protected] 8694 Old Road Website: www.ouh.nhs.uk/geneticslab Headington Accredited to Oxford ISO 15189:2012 OX3 7LE Testing performed at the above address only DETAIL OF ACCREDITATION Materials/Products tested Type of test/Properties Standard specifications/ measured/Range of measurement Equipment/Techniques used HUMAN TISSUES AND FLUIDS Molecular Genetics Documented in-house methods incorporating manufacturer’s Detection of genetic mutations and instructions (where relevant) sequence variants for the purpose of clinical diagnosis Fresh, frozen or fixed human tissue Manual and automated DNA or cells extraction and quantification using: DNA SOP 2005-0159, 2006-0083, 2011 38, 2011 40, 2011 62, 2015 330, 2017 440 CYTO SOP 376, 460, 456 And Tecan Evo-HSM Robot, Promega Maxwell RSC, Grade 2 extraction cabinet, Nanodrop, Glomax Multi+ Fluorometer Genomic DNA extracted in-house Detection of specific mutations for: Non-fluorescent PCR amplification from the sample types listed above • Rare confirmation / followed by Restriction enzyme or received as primary sample type investigation of specific digest and electrophoresis from external source mutations using: • Mitochondrial DNA DNA SOP 2011 49, 2006-0107, analysis, e.g. m.8993T>C/G 2005-0064, 2005-0090, 2006-0002, And Biomek NX-S8 G-Storm and Dyad PCR Machines Genomic DNA extracted in-house Detection of large-scale deletions Non-fluorescent PCR amplification from the sample types listed above (mitochondrial DNA) followed by agarose gel or received as primary sample type electrophoresis from external source Rare confirmation / investigation of using: specific mutations DNA SOP 2011 49, 2005-0062, 2005-0090, 2006-0002, 2005-0184, Sex determination 2005-0154 and G-Storm and Dyad PCR Machines Gel tanks and power packs Assessment Manager: HL Page 1 of 11 Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Oxford University Hospitals NHS Foundation Trust 8694 Accredited to Issue No: 006 Issue date: 13 August 2020 ISO 15189:2012 Testing performed at main address only Materials/Products tested Type of test/Properties Standard specifications/ measured/Range of measurement Equipment/Techniques used HUMAN TISSUES AND FLUIDS Molecular Genetics (cont’d) Documented in-house methods (cont’d) incorporating manufacturer’s Detection of genetic mutations and instructions (where relevant) sequence variants for the purpose of clinical diagnosis (cont’d) Genomic DNA extracted in-house Detection of expansions including Fluorescent PCR amplification from the sample types listed above triplet repeats or microsatellite (including real-time PCR, Triplet or received as primary sample type marker analysis primed PCR, Devyser and ARMS) from external source using fluorescently tagged primers Fragment size analysis in the prior to detection and/or sizing of investigation of the PCR product using • HD commercially available kits or in- • ALS house designed assays using: • FMR1 DNA SOP 2008 4, 2008 14 • SBMA 2006-0051, 2005-0079, 2005-0081, • DM 2005-0082, 2005-0121, 2005-0129, • GREM1 2005-0184, 2006-0013, 2006-0014, • CFTR gene 2006-0027, 2006-0043, 2010 34, 2012 126, 2005-0090, 2006-0002, Microsatellite marker analysis for: 2005-0154, 2010 34, 2014 225 CYTO SOP 376, and • sex determination G-storm and Dyad PCR machines • zygosity ABI 3730 & ABI 7500 • linked markers with analysis using Gene Mapper • Ascertainment of Uni-parental Disomy (UPD) • Microsatellite Instability (MSI) • RAPID prenatal aneuploidy test • Quantitation of mitochondrial DNA copy number Genomic DNA extracted in-house Mitochondrial DNA analysis, e.g. Fluorescent PCR amplification from the sample types listed above m.3243A>G followed by Restriction enzyme or received as primary sample type digest from external source using fluorescently tagged primers prior to detection and/or sizing of the PCR product. DNA SOP 2011 49, 2006-0002, G-storm and Dyad PCR machines ABI 3730 with analysis using Gene Mapper Assessment Manager: HL Page 2 of 11 Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Oxford University Hospitals NHS Foundation Trust 8694 Accredited to Issue No: 006 Issue date: 13 August 2020 ISO 15189:2012 Testing performed at main address only Materials/Products tested Type of test/Properties Standard specifications/ measured/Range of measurement Equipment/Techniques used HUMAN TISSUES AND FLUIDS Molecular Genetics (cont’d) Documented in-house methods (cont’d) incorporating manufacturer’s Detection of genetic mutations and instructions (where relevant) sequence variants for the purpose of clinical diagnosis (cont’d) Genomic DNA extracted in-house Detection of large gene re- Southern blot from the sample types listed above arrangements and large triplet using: or received as primary sample type repeat expansions: DNA SOP 2005-0121, 2005-0079 from external source 2006-0002, 2014 225 (ALS/FTD) • FMR1 and • Mitochondrial DNA re- G-Storm and Dyad PCR machines arrangements Gel tanks, Hybridisation ovens • ALS/FTD Shakers • DM Gel Doc Developer Genomic DNA extracted in-house Detection and quantification of Pyrosequencing from the sample types listed above specific variants using: or received as primary sample type • Mitochondrial disorders (POLG, DNA SOP 2009 26, 2006-0002, from external source LHON) 2005-0101, 2010 34 • other specific mitochondrial and mutations Qiagen PyroMark ID System • BRAF analysis • HCM –associated mito variant, m.4300 Genomic DNA extracted in-house Whole gene screen analysis for Sanger sequencing from the sample types listed above genetic variants causing diseases using: or received as primary sample type and disorders, family testing DNA SOP 2009 23, 2005-0156, from external source (including prenatal and predictive 2012 140 testing), and confirmation of and variants detected by alternative Robots: Biomek NX-S8 and Biomek methods: NX-MC(96) ABI 3730 Analysis of: with analysis using Mutation surveyor software • Familial cardiomyopathy • Lynch syndrome • BRCA1 / BRCA2 • Familial Arrhythmias Assessment Manager: HL Page 3 of 11 Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Oxford University Hospitals NHS Foundation Trust 8694 Accredited to Issue No: 006 Issue date: 13 August 2020 ISO 15189:2012 Testing performed at main address only Materials/Products tested Type of test/Properties Standard specifications/ measured/Range of measurement Equipment/Techniques used HUMAN TISSUES AND FLUIDS Molecular Genetics (cont’d) Documented in-house methods (cont’d) incorporating manufacturer’s Detection of genetic mutations and instructions (where relevant) sequence variants for the purpose of clinical diagnosis (cont’d) Genomic DNA extracted in-house Endocrine disorders, including Sanger sequencing (cont’d) from the sample types listed above endocrine tumour predisposition or received as primary sample type Hyperparathyroidism from external source Hypoparathroidism Disorders of calcium metabolism • Familial Cancers • Craniosynostosis • Pheochromocytoma/paragangli oma • Skeletal dysplasia • Congenital Myasthenic syndrome • Disorders of the retina • Inherited Ataxias • Mitochondrial disorders • Disorders of mitochondrial maintenance and repair Assessment Manager: HL Page 4 of 11 Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Oxford University Hospitals NHS Foundation Trust 8694 Accredited to Issue No: 006 Issue date: 13 August 2020 ISO 15189:2012 Testing performed at main address only Materials/Products tested Type of test/Properties Standard specifications/ measured/Range of measurement Equipment/Techniques used HUMAN TISSUES AND FLUIDS Molecular Genetics (cont’d) Documented in-house methods (cont’d) incorporating manufacturer’s Detection of genetic mutations and instructions (where relevant) sequence variants for the purpose of clinical diagnosis (cont’d) Genomic DNA extracted in-house Gene screening of gene panels for from the sample types listed above genetic variants causing diseases Next generation sequencing with or received as primary sample type and disorders including: target enrichment using TWIST from external source Biosciences generated probes. • Familial Cardiomyopathy DNA SOP 2014-227, 2019-603. Veriti PCR Machines, • Inherited eye conditions GloMax®-Multi+’ Fluorometer, Agilent 2200 Tape Station • Ataxia Illumina NGS Platforms (either in house or located within the • Joubert & Ciliopathies Wellcome Trust Centre for Human Genetics. • Familial arrhythmia Analysis Analysis of DNA sequence data • Familial cancers generated either internally or externally using in-house validated • Mitochondrial bioinformatics pipeline DNA SOP 2016-402, 2019-602, • Painful channelopathies 2019-604, 2019-605, 2019-606, 2020-620, 2020-621, 2020-622, • Epilepsy 2020-628, 2020, 629. 2020-630. • Familial Hypercholesterolaemia • Non-malignant haematology DNA sequence data Diseases and disorders listed for Analysis of DNA sequence data Next generation sequencing
Load more

Recommended publications
  • YOUNG PERSON with HAEMOPHILIA (12-15Yrs) PARTICIPANT INFORMATION SHEET
    [Emi + Me Young Persons with Haemophilia PIS (12-15yrs) v7 Dated 16 April 2020: IRAS number 248511] Oxford Haemophilia & Thrombosis Centre Churchill Hospital Old Road Headington Oxford OX3 7LE YOUNG PERSON WITH HAEMOPHILIA (12-15yrs) PARTICIPANT INFORMATION SHEET Study Title: Emi and Me: An Exploration of Emicizumab on the lives of people with haemophilia and inhibitors and their families Study Sponsor: Haemnet Protocol Number: Version 4 dated 26 November 2019 Principal Investigator: Simon Fletcher Co-investigators: Dr Kate Khair, Luke Pembroke Introduction This study is talking to people about what it is like to use Emicizumab (Hemlibra®) in people with haemophilia and inhibitors. We also want to find out about impact of Emicizumab use on the lives of your close family members (parents and sisters). We will get this information through talking to you all. The study will also form part of a body of work given as evidence for a PhD currently being undertaken by the Principal Investigator Please read this information carefully and talk to your mum, dad, carer or hospital haemophilia team if you have any questions. Please ask us if there is anything that is not clear or if you would like more information, our contact details are at the end of this information sheet. If you don’t want to take part that is fine. Why are we doing this study? From this study we want to find out what it is like to use Emicizumab for you and your close family members. We also want to understand what you think about your haemophilia care now and how it might be in the future.
    [Show full text]
  • Risk of Infection
    Adapted from Oxford Radcliffe Hospitals NHS Trust Cancer Care and ‘Risk of Infection, Information sheet’ Clinical Haematology Department, Cancer and Haematology Centre Haematology Service Churchill Hospital, Oxford Risk of Infection How can I help reduce healthcare associated infections? Infection control is important to the well-being of our patients and for that reason we have infection control procedures in place. Keeping your hands clean is an effective way of preventing the spread of infections. We ask that you, and anyone visiting you, use the hand rub (special gel) available at the main entrance of the hospital and at the entrance to every ward before coming in to and after leaving the ward or Important information for all patients hospital. In some situations hands may need to be washed at the sink using soap and water rather than using the hand If you require an interpreter or need a document in another rub. Staff will let you know if this is the case. language, large print, Braille or audio version please ask for assistance. www.buckshealthcare.nhs.uk Author: Haematology Leaflet code: CISS - 122 Issue date: January 2015 Version: 2 Reviewed: January 2017 Review date: January 2019 How to contact us When you have been diagnosed with a condition that affects your bone marrow or lymph glands, you are much Emergency Phone No. more at risk of infection than a member of the general public. This risk is high because it is much more difficult for Oncology/Haematology CCHU you to fight infections. Stoke Mandeville Hospital This can be a very serious situation so needs to be (Monday – Friday 9.00am – 5.00pm) acted on immediately.
    [Show full text]
  • Director of Infection Prevention and Control (DIPC) Annual Report 2017/18
    Trust Board Meeting in Public: Wednesday 12 September 2018 TB2018.84 Title Director of Infection Prevention and Control (DIPC) Annual Report 2017/18 Status For information History Previously presented at Hospital Infection Prevention and Control Committee (HIPCC) Board Lead(s) Dr Tony Berendt Key purpose Strategy Assurance Policy Performance TB2018.84 Infection Prevention & Control Annual Report 2017/18 Page 1 of 32 Oxford University Hospitals NHS Foundation Trust TB2018.84 Figure 1: A graphical summary of key events in infection control activity in 2017-18 TB2018.84 Infection Prevention & Control Annual Report 2017/18 Oxford University Hospitals NHS Foundation Trust TB2018.84 Executive Summary 1. The annual report of the Director of Infection Prevention and Control (DIPC) is a mandated report to the Board that describes the structure and key activities of the infection prevention and control (IPC) team. These activities include surveillance, outbreak investigation and management, audit, and teaching and training. 2. Methicillin-resistant Staphylococcus aureus (MRSA) Bacteraemia Zero avoidable MRSA bacteraemias are permitted by national mandate. There was one unavoidable post-48 hour bacteraemia in 2017/18, and no avoidable bacteraemias. There were 3 pre-48 hour cases of MRSA bacteraemia, considered to represent the development of infection prior to hospitalisation. 3. Clostridium difficile There were 72 OUH apportioned cases identified after three days of admission for 2017/2018 against an upper set limit of 69. 4. Methicillin-sensitive Staphylococcus aureus (MSSA) Bacteraemia There were a total of 36 incidents of post-48 hour MSSA bacteraemia, a lower figure than the 41 cases last year. 5. Gram negative blood stream Infections (GNSBI) April 2017 saw the introduction of additional nationally mandated GNBSI surveillance.
    [Show full text]
  • It's Not Just a Walk in the Park !
    It’s Not Just a Walk in the Park ! BACK BY POPULAR DEMAND and this time it really isn’t a Walk in the Park! 5 mile sponsored walk supporting your Hospital Charity Sunday 5 October 2014 10.30am You decide which Ward or Department you would like to support! Oxford Radcliffe Hospitals Charitable Funds and Oxford Health Charitable Funds Support Your Hospital Charity Route Map About the event Sunday 5 October 2014 10.30am It’s Not Just A Walk In The Park is back by popular demand and this time it really isn’t a walk in the park! New for 2014 our sponsored 5 mile walk route will take in three of the four Oxford University Hospital sites and the Warneford Hospital as, after all, the event is about raising Johnmuch neededRadcliffe funds Hospital. Churchill Hospital. Nuffield Orthopaedic Centre. for the hospitals and you will be able to specify exactly whichHorton Fund, ward General or Hospital. John Radcliffe Hospital. Churchill Hospital. Nuffield department you would like to support. Orthopaedic Centre. Horton General Hospital. John Radcliffe Hospital. It might be a ward that you or a loved one has been treated in andChurchill this will Hospital. Nuffield Orthopaedic Centre. Horton General Hospital. be your way of saying ‘thank you’ along with your family and friends. JohnIf you Radcliffe Hospital. Churchill Hospital. Nuffield Orthopaedic Centre. are unsure of the name of the Fund you would like to support please callHorton the General Hospital. John Radcliffe Hospital. Churchill Hospital. Nuffield Fundraising Office on 01865 743444 or email at [email protected] and we will be happy to identify the correct Fund for you.
    [Show full text]
  • Annual Report 2006 2
    1. Oxford Radcliffe Hospitals NHS Trust Annual Review 2006 Annual Report 2006 2. Oxford Radcliffe Hospitals NHS Trust Annual Review 2006 Foreword Sir William Stubbs, Chairman The Oxford Radcliffe Hospitals NHS Trust efficient journey through their treatment. (ORH) has an international reputation for By improving our performance in this way clinical excellence and in recent years the and removing bottlenecks and duplication Trust has been able to improve its facilities we will not only enhance patients’ and efficiency to match and support this experience, we will reduce costs. This reputation. work is an obvious extension of the macro- view provided by the Strategic Review of This has taken us from being a no-star our services that we have been undertaking trust, with costs above the average, to over the past two years. a two-star trust that is among the most efficient Trusts in England. This journey has The task ahead is not a small one, meant reduced waiting times, improved but it is achievable, particularly with diagnostic equipment, new services and the extraordinary dedication and new and improved infrastructure. resourcefulness of our staff. Despite this exemplary performance we Despite the challenging times of the past and beyond, with state-of-the-art cancer are, however, in a position where the year, we have had the pleasure of seeing the services. A particularly important element county’s funding levels have for some time new Oxford Children’s Hospital and new of the Private Finance deal that has not matched the levels of demand - and West Wing nearing completion on the John made this project possible is the built- this meant that last year we received £12.4 Radcliffe site.
    [Show full text]
  • Global Atlas of Palliative Care at the End of Life
    Global Atlas of Palliative Care at the End of Life January 2014 Acknowledgements and authorship Edited by: Stephen R. Connor, PhD, Senior Fellow to the Worldwide Palliative Care Alliance (WPCA). Maria Cecilia Sepulveda Bermedo, MD, Senior Adviser Cancer Control, Chronic Diseases Prevention and Management, Chronic Diseases and Health Promotion, World Health Organization. The views expressed in this publication do not necessarily represent the decisions, policy or views of the World Health Organization. This publication was supported in part by a grant from the Open Society Foundations’ International Palliative Care Initiative. Special thanks to Mary Callaway and Dr Kathleen Foley. Contributing writers: Sharon Baxter, MSW, Canadian Hospice Palliative Care Association, Canada Samira K. Beckwith, ACSW, LCSW, FACHE, Hope Hospice, Ft Myers, FL, USA David Clark, PhD – University of Glasgow, Scotland James Cleary, MD – Pain and Policies Study Group, Madison, WI, USA Dennis Falzon, MD – WHO Global TB Program, WHO Geneva Philippe Glaziou, MD, MPhil, Dip Stat – WHO Global TB Program, WHO Geneva Peter Holliday, St. Giles Hospice, Litchfield, England Ernesto Jaramillo, MD – WHO Global TB Program, WHO Geneva Eric L. Krakauer, MD, PhD – Harvard Medical School Center for Palliative Care, Boston, MA, USA Suresh Kumar, MD – Neighborhood Network in Palliative Care, Kerala, India Diederik Lohman – Human Rights Watch, New York, USA Thomas Lynch, PhD – International Observatory for End of Life Care, Lancaster, England Paul Z. Mmbando (MBChB, MPH, DrH) Evangelical Lutheran Church, Arusha, Tanzania Claire Morris, Worldwide Palliative Care Alliance, London, England Daniela Mosoiu, MD – Hospice Casa Sperantei, Brasov, Romania Fliss Murtagh FRCP PhD MRCGP, Cicely Saunders Institute, Kings College London Roberto Wenk, MD – Programa Argentino de Medicina Paliativa Fundación, Argentina In addition, the editors would like to thank the following: All WHO collaborating centres on palliative care (see appendix for details) Ricardo X.
    [Show full text]
  • Speciality Training Infectious Diseases with Microbiology Or
    Speciality Training Infectious Diseases with Microbiology or General (Internal) Medicine Training Programme Director: Dr Bridget Atkins Trainee Representative: Dr Elham Khatamsaz Introduction ID/micro is currently a six year training programme with 12 months credit allowed if trainees obtain separate research funding during a period out of programme (OOPR). ID/GIM is a five year programme. In August 2015 a new combined infection training programme will be introduced subject to GMC approval. This will constitute 2 years of core infection training followed by either 2 years of Medical Microbiology (MM), Medical Virology (MV) or Infectious Diseases (ID) or 3 years to obtain a CCT in ID/MM or ID/MV or ID/GIM. In Oxford the programme offers training for a CCT in ID/Micro or ID/GIM. Entry is at ST3 level after achievement of Core Medical Training and MRCP (or equivalent). Trainees currently enter on the 2010 Med Micro (RCPath) and Infectious Diseases (RCP) curricula and are required to fulfil the work competencies, work placed based assessments and knowledge based assessments for both. Trainees in 2015 will be required to be on the latest curriculum which will be the new combined infection training (CIT) and relevant Higher Specialist training (HST) programme as above. Those doing general internal medicine with ID will need to fulfil the requirement of the RCP GIM curriculum. Trainees will undergo posts in microbiology/virology (in Oxford and/or Aylesbury), infection consults, infectious diseases ward, bone infection unit and GIM/ID (Oxford and/or Slough). The deanery collaborates with Wessex deanery and opportunities exist for delivery of ID in Southampton too.
    [Show full text]
  • Advanced Practice in Endocrinology Nursing Sofia Llahana · Cecilia Follin Christine Yedinak · Ashley Grossman Editors
    Advanced Practice in Endocrinology Nursing Sofia Llahana · Cecilia Follin Christine Yedinak · Ashley Grossman Editors Advanced Practice in Endocrinology Nursing With Paediatric Editors Kate Davies and Margaret F. Keil Editors Sofia Llahana Cecilia Follin School of Health Sciences, City Department of Oncology University of London Skåne University Hospital London Lund UK Sweden Christine Yedinak Ashley Grossman Northwest Pituitary Center Churchill Hospital Oregon Health and Sciences University University of Oxford Portland, OR Oxford USA UK ISBN 978-3-319-99815-2 ISBN 978-3-319-99817-6 (eBook) https://doi.org/10.1007/978-3-319-99817-6 Library of Congress Control Number: 2018968596 © Springer Nature Switzerland AG 2019, Corrected Publication 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.
    [Show full text]
  • Celebrating 13 Decades of Nurse Education 125 YEARS of NURSE EDUCATION in OXFORD
    Celebrating 13 decades of nurse education 125 YEARS OF NURSE EDUCATION IN OXFORD Welcome to the 125 Years of Nurse Education in Oxford celebration booklet ACKNOWLEDGEMENTS We wish to thank the following This booklet details the last 13 decades of nurse people or organisations for their education in Oxford and Swindon. We are grateful help in compiling this booklet: to the people who have taken time to share their experiences of nurse education. DESIGNER ■ Flora Hands, Carline Creative The training and education of health care professionals has long been a cornerstone of life in Oxford and in AUTHORS the 20th and 21st Centuries Oxford Brookes University ■ Xante Cummings has played its own vital role in working with local ■ Annie Thompson-Lynch partners to provide professional healthcare education. ■ Dr Liz Westcott Nurse training in Oxford can trace its beginnings back to 1782. Then a non-regulated training, the early THE RADCLIFFE GUILD OF NURSES – beginnings of a formal nurse education, started in 1891 PERSONAL REMINISCENCES FROM: at the Radcliffe Infirmary on Woodstock Road. ■ Rita Bayley The records, many of which we have accessed to write ■ Theresa Bentley this booklet, provide a fascinating history. Between ■ Sue Bradshaw 1921 and 1991, 7948 nurses’ names were recorded. ■ Nurse training continued at the Radcliffe Infirmary and Nicky Brennan in 1979 the John Radcliffe 2 site was opened and the ■ Anne Carter ‘The School of Nursing’ transferred to this new site. ■ Mary Campbell In the mid 1980s Malcolm Ross, then Chief Nursing ■ Mary Dickman Officer in Oxford, Pam Jones the Head of Nursing ■ June Fisher Education in Oxford entered into discussions with ■ Eileen Forbes the then Vice Chancellor, Clive Booth and senior staff ■ at Oxford Polytechnic.
    [Show full text]
  • BIOPIC: Biological Magnetic Resonance Imaging Parameters in Oropharyngeal Squamous Cell Carcinoma
    BIOPIC PROTOCOL: V0.3 21OCT2016 BIOPIC: Biological Magnetic Resonance Imaging Parameters in oropharyngeal squamous cell carcinoma Internal Reference Number / Short title: BIOPIC Ethics Ref: 17/WA/0033 IRAS Ref: 213131 Date and Version No: October 21st 2016 V0.3 Chief Investigator: Professor Fergus Gleeson Department of Radiology Churchill Hospital Roosevelt Drive Oxford OX3 7LE Email: [email protected] Investigators: Dr Tessa Greenhalgh Clinical Research Fellow Gray Institute for Radiation Oncology & Biology University of Oxford Old Road Campus Research Building Oxford OX3 7DQ Tel: +44 (0) 1865 617330 Email: [email protected] Dr Ketan Shah Consultant in Clinical Oncology Department of Oncology Churchill Hospital Roosevelt Drive Oxford OX3 7LE Email: [email protected] Professor Daniel Bulte Engineering Science Institute of Biomedical Engineering Old Road Campus Research Building Roosevelt Drive Oxford OX3 7DQ Email: [email protected] Protocol Version 0.3 21 October 2016 BIOPIC: Biological Magnetic Resonance Imaging Parameters in oropharyngeal squamous cell carcinoma IRAS Project number: 213131 Chief Investigator: Professor Fergus Gleeson Page 1 of 27 BIOPIC PROTOCOL: V0.3 21OCT2016 Dr Brian Burns MRI Physics Department of Oncology University of Oxford Old Road Campus Research Building Oxford OX3 7DQ Email: [email protected] Dr Nia Taylor Consultant Radiologist Department of Radiology Churchill Hospital Roosevelt Drive Oxford OX3 7LE Email: [email protected] Dr Ketan A. Shah Consultant Pathologist Cellular Pathology John Radcliffe Hospital Headley Way Oxford OX3 9DU [email protected] Sponsor: University of Oxford Funder: Oxford Cancer Imaging Centre (OCIC) Oxfordshire Health Services Research Committee (OHSRC) Chief Investigator Signature: ........................................
    [Show full text]
  • Professor John Wass Biography
    Professor John Wass Biography John Wass is the Professor of Endocrinology at Oxford University and was Head of the Department of Endocrinology at the Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital Oxford, UK until 2012. His research interests include all pituitary tumours, especially acromegaly, adrenal disease, angiogenesis in endocrinology, and the genetics of osteoporosis and thyroid disease. Since 1975 he has published over 385 articles in scientific journals and as well as written many reviews and chapters in textbooks including the Oxford Textbook of Medicine and DeGroot’s Textbook of Endocrinology. He has also edited a number of different textbooks including the Oxford Textbook of Endocrinology, Clinical Endocrine Oncology and the Oxford Handbook of Endocrinology (3 editions). He was President of the European Federation of Endocrine Societies from 2001-2003 and was Chairman of the Society for Endocrinology (2006- 2009. He has also served as President of the Pituitary Society. This year he received the Lifetime Achievement Award by the Pituitary Society in the USA. He has won a number of prizes and given named lectures including the Jubilee Prize of the Society for Endocrinology. He was recently in June 2015 awarded the Distinguished Physician of the Year Award by the American Endocrine Society; the first non American to ever receive this award. Amongst his charitable activities, he is Patron of the St. Pauls Way School (with Professor Brian Cox) and he founded the Pituitary Foundation. He was Academic Vice President of the Royal College of Physicians in London, from August 2012 until August 2015. He chaired the Royal College of Physicians Working Party ‘Action on Obesity: Comprehensive Care for All’ published in January 2013, and has been involved improving services for patients with obesity.
    [Show full text]
  • Having a Blood Test Blood Tests Help Us Diagnose Your Illness and Monitor Your Treatment
    Oxford University Hospitals NHS Trust Having a blood test Blood tests help us diagnose your illness and monitor your treatment. We understand that some people find them unpleasant, and we try to treat you with care and consideration. How to find us John Radcliffe Hospital Outpatients Blue Area, Level 2 Monday 9.00am - 1.00pm Tuesday to Friday 9.00am - 4.45pm John Radcliffe Hospital Women’s Centre Outpatients Level 1 Monday and Friday 9.00am - 1.00pm Tuesday to Thursday 9.00am - 1.00pm and 1.30pm - 4.30pm Children’s Hospital Paediatric Outpatients LG1 Monday to Thursday 10.00am - 4.45pm Friday 10.00am - 12.45pm Churchill Hospital Cancer / Haematology Outpatients Level 0 Monday to Thursday 8.30am - 4.45pm Friday 8.30am - 4.00pm Horton General Hospital Pathology Laboratory Monday, Tuesday and Thursday 9.00am - 12.00 noon What to do when you arrive John Radcliffe Hospital: please take a ticket from the wall dispenser and wait for your number to be called. Women’s Centre: please take a seat outside the department and wait to be called Children’s Hospital: please go to reception Churchill Hospital: please take a ticket from the wall dispenser and wait in section A Horton General Hospital: please go to the reception desk. Please tell us if you have had any problems with blood tests before, such as fainting. While waiting we try to see everyone as quickly as possible, but delays can occur. We will inform you of any delays when you arrive. Please remember: we can only perform a blood test if you have a blood request form.
    [Show full text]